Sent from my iPad Begin forwarded message:
Sent from my iPad
Begin forwarded message:
From: Inside Precision Medicine Webinar <update@mail.insideprecisionmedicine.com> Date: April 7, 2025 at 1:03:11 PM GMT-3 To: mxh5000@gmail.com Subject: Marta, are you joining this upcoming webinar? Reply-To: emailreply@insideprecisionmedicine.com
View in browser
Optimizing Biomarker Detection Using Multi-Modal Cancer Genomic Profiling In this Inside Precision Medicine webinar, our expert speakers will provide an overview of the current state of CGP technology and why adopting a multi-modal testing approach that integrates DNA and RNA sequencing, immunohistochemistry (IHC), and gene expression profiling (GEP) is essential for optimal biomarker detection. They will share real-world data from over 20,000 solid tumor specimens that demonstrate the clinical impact of CGP on biomarker detection rates, test success, and turnaround times. They will also present case studies illustrating how multi-modal profiling enhances therapeutic decision-making.
Key learnings from the webinar include:
How CGP integrates DNA and RNA sequencing, IHC, and GEP to identify clinically actionable biomarkers A review of real-world data demonstrating the success rates, detection rates, and clinical relevance of a multi-modal CGP approach Examples of real-world oncology case studies that illustrate how comprehensive profiling informs treatment selection and improves patient outcomes Tuesday, April 8, 2025
8:00 am PT, 11:00 am ET, 17:00 CEST
REGISTER FREE PRESENTED BY
Rebecca Previs, MD
Director of Medical Affairs Labcorp Oncology
Kyle Strickland, MD, PhD
Director of Medical Affairs Labcorp Oncology
Michelle Green, PhD
Sr. Manager, Oncology Genomics Program, Medical Affairs Labcorp Oncology
INSIDE THE WEBINAR Comprehensive genomic profiling (CGP) has established itself as an important tool for identifying actionable biomarkers and optimizing treatment strategies for precision oncology. However complex testing modalities, tissue limitations, and the rapid pace of discovery of new cancer biomarkers make broad application difficult.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
REGISTER NOW PRODUCED WITH SUPPORT FROM
Inside Precision Medicine
Mary Ann Liebert, Inc., a Sage Company
140 Huguenot Street
New Rochelle, NY 10801
You have received this email at mxh5000@gmail.com
Unsubscribe Manage Preferences